Stocktoria
Tarsus Pharmaceuticals, Inc. TARS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-16
Tarsus Pharmaceuticals, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -15.7% | -65.9% | -820.5% | -242.9% | -21.3% |
| Net margin | -14.7% | -63.2% | -778.9% | -240.5% | -24.2% |
| FCF margin | -4.9% | -46.2% | -682.0% | -191.9% | 5.5% |
| Return on assets | -11.8% | -30.7% | -51.2% | -27.2% | -7.7% |
| Return on equity | -19.3% | -51.5% | -69.0% | -32.2% | -8.3% |
| Debt / equity | 0.21× | 0.32× | 0.15× | 0.10× | 0.00× |
| Current ratio | 3.85 | 4.42 | 6.93 | 14.61 | 15.33 |
| Revenue growth | 146.7% | 948.6% | -32.4% | -54.7% | — |
Source: SEC EDGAR filings · CIK 0001819790 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.